🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the bacteria, according to health experts.

An International Challenge

The sexually transmitted infection are increasing globally, with estimates suggesting in excess of 82 million instances per year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, the spread of superbugs and the extremely scarce available drugs currently available.”

Medical experts are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has designated it as a "critical concern". Recent surveillance found that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Drugs Receive Approval

Zoliflodacin, also known as Nuzolvence, was cleared by the American regulatory agency in mid-December for treating gonorrhoea. This infection can lead to major issues, including the inability to conceive. Experts hope that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, gained clearance in close succession. This drug, which is additionally indicated for urinary tract infections, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

An Innovative Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone represents a huge turning point in the therapy of superbug gonorrhoea, which until now has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

According to findings published in a major medical journal, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This establishes an comparable level with the typical regimen, which combines two antibiotics. The trial included hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the authority to license and sell the drug in many developing nations.

Clinicians directly involved have voiced optimism. The availability of a one-pill regimen like this is hailed as a "revolutionary step" for gonorrhoea control. This is considered crucial to alleviate the strain of the infection for individuals and to prevent the spread of untreatable gonorrhoea globally.